Beam Therapeutics Files 2024 10-K
Ticker: BEAM · Form: 10-K · Filed: Feb 25, 2025
Sentiment: neutral
Topics: 10-K, biotechnology, annual-report
TL;DR
Beam Therapeutics filed its 2024 10-K. Check financials.
AI Summary
Beam Therapeutics Inc. filed its 2024 10-K on February 25, 2025, reporting its fiscal year ending December 31, 2024. The company, focused on biological products, is incorporated in Delaware and headquartered in Cambridge, MA. Key financial details and operational aspects for the fiscal year 2024 are presented in this filing.
Why It Matters
This filing provides a comprehensive overview of Beam Therapeutics' financial health and operational performance for the past fiscal year, crucial for investors and stakeholders to assess the company's trajectory.
Risk Assessment
Risk Level: medium — As a biotechnology company, Beam Therapeutics operates in a highly regulated and research-intensive industry with inherent risks related to drug development and market approval.
Key Players & Entities
- Beam Therapeutics Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-02-25 (date) — Filing date
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA 02139 (address) — Company business and mailing address
FAQ
What is Beam Therapeutics' primary business focus?
Beam Therapeutics Inc. is primarily involved in the business of Biological Products (No Diagnostic Substances) [2836].
When did Beam Therapeutics' fiscal year 2024 end?
Beam Therapeutics' fiscal year ended on December 31, 2024.
On what date was this 10-K filing submitted?
This 10-K filing was submitted on February 25, 2025.
What is the company's state of incorporation?
Beam Therapeutics Inc. is incorporated in Delaware (DE).
What is the company's SEC file number?
The SEC file number for Beam Therapeutics Inc. is 001-39208.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 25, 2025 regarding Beam Therapeutics Inc. (BEAM).